PRODUCTEN

Practical documents such as Practical Guide, Patient Brochure,… 

Prof. Dr. Stefan Kasper-Virchow, an international Key Opinion Leader, highlights the FRESCO-2 study key outcomes and shares his clinical perspective from Germany. 

FRESCO-2 was a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla + best supportive care (BSC) vs. Placebo + BSC.^1,2

In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla were manageable and predictable^1-3

Fruzaqla is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.¹

Simple, convenient dosing with once-daily oral Fruzaqla